Clinical Trials Sponsored by ICOS Corporation

Total 6610 results

ICOS Corporation

Completed

A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis

Pneumonia | Sepsis

United States
ICOS Corporation

Completed

Interstitial Cystitis

Interstitial Cystitis

United States
ICOS-Texas Biotechnology
ICOS Corporation; Texas Biotechnology Corporation

Unknown

Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension

Pulmonary Hypertension

United States, Canada
ICOS Corporation
Suntory Pharmaceutical

Terminated

Safety and Efficacy of Recombinant Human Platelet-Activating Factor Acetylhydrolase for the Treatment of Severe Sepsis

Sepsis

United States
Eli Lilly and Company
ICOS Corporation

Completed

Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs

Hypertension, Pulmonary

United States, Belgium, Canada, France, Germany, Ireland, Italy, Japan, Spain, United Kingdom
Eli Lilly and Company
ICOS Corporation

Completed

Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia

United States
Eli Lilly and Company
ICOS Corporation

Completed

PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension

Pulmonary Hypertension

France, United States, Italy
Eli Lilly and Company
ICOS Corporation

Completed

A Study to Evaluate the Efficacy and Safety of 2.5mg and 5mg Tadalafil Given Once a Day to Men With Erectile Dysfunction

Erectile Dysfunction

United States
Eli Lilly and Company
ICOS Corporation

Completed

Study For Which Treatment, Tadalafil or Sildenafil, is Preferred For Problems Getting or Maintaining an Erection

Impotence

United Kingdom
Eli Lilly and Company
ICOS Corporation

Completed

Studying the Preference of Tadalafil to Sildenafil in Men With Problems Getting an Erection Across Nations

Impotence

Brazil
Eli Lilly and Company
ICOS Corporation

Completed

Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems (PILUTS)

Prostatic Hyperplasia | Prostate

United States
Eli Lilly and Company
ICOS Corporation

Completed

Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life

Impotence

United States, Austria, France, Germany, Mexico
Eli Lilly and Company
ICOS Corporation

Completed

Study of Tadalafil for the Treatment of Diabetic Patients With Symptoms of Upset Stomach and Delayed Stomach Emptying

Gastroparesis

Canada
Eli Lilly and Company
ICOS Corporation

Completed

Tadalafil in Subjects With Mild to Moderate Hypertension

Hypertension

United States
Eli Lilly and Company
ICOS Corporation

Completed

A Study of Semen Characteristics After 9 Months of Daily Tadalafil 20 mg

Erectile Dysfunction

United States
Eli Lilly and Company
ICOS Corporation

Completed

Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia

United States, Greece, Portugal
Eli Lilly and Company
ICOS Corporation

Completed

Effect of Tadalafil on the Quality of Life and Sexual Life in Erectile Dysfunction

Erectile Dysfunction | Impotence

Finland
Eli Lilly and Company
ICOS Corporation

Completed

A Study of Visual Effects of Erectile Dysfunction Medications Dosed Daily for Six Months

Erectile Dysfunction

United States
Eli Lilly and Company
ICOS Corporation

Completed

Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury

Erectile Dysfunction | Spinal Cord Injuries

United States
Eli Lilly and Company
ICOS Corporation

Completed

Study to Determine a Preference Between Sildenafil or Tadalafil Treatment for Problems Getting an Erection

Impotence

Korea, Republic of
Eli Lilly and Company
ICOS Corporation

Completed

To Determine Effect and Safety of Tadalafil Taken by Men of Different Races and With Different Diseases When Needed for Erections

Impotence

United States
Eli Lilly and Company
ICOS Corporation

Completed

To Determine How Different Doses of Tadalafil Work on Getting and Keeping an Erection 26 or 36 Hours After Taking

Impotence

United States
Eli Lilly and Company
ICOS Corporation

Completed

Determine Safety and Effectiveness of Tadalafil in Asian Men When Taken as Needed for Getting and Keeping an Erection

Impotence

China
Eli Lilly and Company
ICOS Corporation

Completed

Study the Safety and Effectiveness of Tadalafil in Men With Diabetes Who Have Problems Getting and Keeping an Erection

Impotence

Germany
Eli Lilly and Company
ICOS Corporation

Completed

Study the Safety and Effectiveness of Tadalafil in Men With Problems Getting or Maintaining an Erection When Taken Prior to Desiring an Erection

Impotence

Japan
Eli Lilly and Company
ICOS Corporation

Completed

Determine If the Stress That Comes With Not Developing an Erection Affects Tadalafil Effects

Impotence

Sweden
Boston Scientific Corporation
ICON plc

Completed

Maximizing CRT Delivery by Using MultipolAr Coronary Sinus Lead FamiLy ACUITY® X4 - RALLY X4 Study (RallyX4)

Heartfailure

Spain, Belgium, Netherlands, Hong Kong, Italy, France, Finland, Switzerland, Israel, Germany, United Kingdom, Colombia, Singapore, Denmark, Portugal, Japan, Austria, Ireland
Boston Scientific Corporation
ICON plc

Completed

Optimizing Pacing Therapy by Using Multi-Programmable Pulse Generators for Cardiac Resynchronization Pacing (CRT-P) (Rally CRT-P)

Post Market Surveillance Study Following Clinical Routine

Germany, Finland
Boston Scientific Corporation
ICON Clinical Research

Completed

Heart Failure and Sudden Cardiac Death Japan Registry (HINODE)

Heart Failure | Arrhythmias, Cardiac | Sudden Cardiac Death

Japan
Golden Biotechnology Corporation
ICON Clinical Research

Completed

Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC

Non-small Cell Lung Cancer Stage IV

United States, Taiwan
AstraZeneca
Covance; ICON plc; PHT Corporation

Terminated

Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States
Celgene Corporation
ICON Clinical Research

Completed

Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality

Myelodysplastic Syndromes

Germany, Israel, United Kingdom, Spain, Belgium, Italy, France, Netherlands, Sweden
Green Cross Corporation
ICON Clinical Research

Terminated

Safety Study of MG1102 in Patients With Solid Tumors

Solid Tumors

Korea, Republic of
GenMont Biotech Incorporation
Biomedical Development Corporation

Completed

the Efficacy and Safety of Probiotics eN-Lac® Capsules of Children With Perennial Allergic Rhinitis (PAR)

Probiotics | Perennial Allergic Rhinitis | Lactobacillus Paracasei GMNL-32 (eN-Lac®)

Taiwan
GlaxoSmithKline
ICON plc

Completed

FF/UMEC/VI Inhaler: Qualitative Analysis and Subject Preference Survey

Pulmonary Disease, Chronic Obstructive

United Kingdom
Mallinckrodt
ICON plc

Completed

Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease

Crohn's Disease

Belgium, Germany, United States, Austria
Icon Genetics GmbH

Completed

Autologous Vaccine for Follicular Lymphoma

Lymphoma, Follicular

United States
ICON Bioscience Inc

Terminated

Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients

Ocular Inflammation

United States
Jazz Pharmaceuticals
ICON plc; Invitae Corporation; Wake Up Narcolepsy; Narcolepsy Network

Completed

A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy

Narcolepsy

United States
Oculis
ICON plc

Recruiting

Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema (DIAMOND-2)

Diabetic Macular Edema

United States
Adaptimmune
ICON plc

Recruiting

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

Melanoma | Head and Neck Cancer | Esophageal Cancer | Ovarian Cancer | Endometrial Cancer | Urothelial Cancer | Gastric (Stomach) Cancer | Esophagogastric Junction (EGJ) | Non-small Cell Lung (NSCLC)

United States, Canada, Spain, Belgium
Eicos Sciences, Inc.

Completed

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)

Raynaud's Phenomenon Secondary to Systemic Sclerosis

United States
Eicos Sciences, Inc.

Completed

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)

Raynaud Phenomenon Secondary to Systemic Sclerosis

United States
GlaxoSmithKline
ICON plc

Completed

Study of Subjects With Diabetic Foot Ulcer (DFU)

Diabetic Foot

United States
ICON Bioscience Inc

Completed

Efficacy and Safety of IBI-10090 in Ocular Surgery Patients

Inflammation Associated With Cataract Surgery

United States
Ixchelsis Limited
HealthCore-NERI; Novotech (Australia) Pty Limited; ICON plc; PHT Corporation

Completed

IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)

Premature Ejaculation

United States, Australia
AstraZeneca
ICON plc

Recruiting

Observational Study Protocol: LIVER-R (LIVER-R)

Hepatobiliary Cancers

United States, Germany, Italy
Adaptimmune
ICON plc

Terminated

ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)

Esophageal Cancer | Esophagogastric Junction Cancer

United States, Canada, United Kingdom, Spain, France
ICON Bioscience Inc

Terminated

Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery

Inflammatory Reaction Due to Ocular Lens Prosthesis

United States
ICON Bioscience Inc

Completed

Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery

Cataract

United States

Clinical Trials Sponsored by ICOS Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations